Strengthened balance sheet during the first quarter of 2021 with the closing of two direct offerings totaling $22.8 million in gross proceeds and $3.3 million from the exercise of warrants…
– Dr. Douglas Lind brings over 30 years of healthcare and capital markets experience to the board – NEW YORK, March 18, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first…
NAPLES, Fla., March 15, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David…
– License has the Potential to Expand Enveric’s Planned Capabilities to Address Cancer Treatment Side Effects – – Innovative Conjugation Platform Aims to Provide Superior Therapeutic Outcomes for Patients by…
Enveric and PureForm to Develop High-Quality, Consistent, Pure CBD Formulations and Delivery Technology for Treating Pain and Inflammation Resulting from Cancer Treatments NAPLES, Fla., Feb. 25, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or…
NAPLES, Fla., Feb. 12, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients,…
NAPLES, Fla., Feb. 9, 2021 — Enveric Biosciences Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients,…
Advancing pipeline with naturally occurring and synthetic compounds initially focused on the development of cannabinoids for pharmaceutical use Enveric has assembled a highly accomplished executive team, Board of Directors and…
NAPLES, Fla., Jan. 15, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing…
NAPLES, Fla., Jan. 12, 2021 — Enveric Biosciences Inc. (NASDAQ: ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it…